Q-REstrain is a therapeutic approach based on microRNA molecules with the ability to regulate the expression of specific target genes. The underlying mechanism, RNA interference (RNAi), has been successfully applied in the treatment of various diseases, including cancer, viral, and respiratory conditions. By targeting and degrading messenger RNA (mRNA) molecules, RNAi helps suppress the production of proteins associated with disease progression, a strategy widely used in cancer therapy and in the treatment of other diseases.
Q-REstrain utilizes microRNAs isolated from the patient’s own sample, designed to degrade specific, overexpressed mRNA molecules. This process helps restore normal gene expression levels.
As a non-manipulated, autologous therapy, Q-REstrain is created uniquely for each patient and is available exclusively through the RGCC network.

Clavic-Q-RE is a non-manipulated, adoptive cell therapy aiming to generate a robust anti-tumor immune response. Clavi-Q-RE contains different cell populations, isolated from the patient’s sample. They include monocytes, natural killer cells, as well as dendritic cells that are already activated in vivo against tumor antigens, which are expressed on cancer samples, cytotoxic T lymphocytes, and plasma cells that have already been differentiated in vivo against tumor antigens. Clavic-Q-RE is for autologous use only and is provided through the RGCC network.

Vaccine Prep (ATA) is a new type of immunotherapy that activates or strengthens specific immune cells. The body's own cells are specifically designed to recognize and destroy cancer cells. We use the cellular fragments of dying tumor cells (CTCs). These include organelles, mitochondria, cell membranes, cellular RNA and DNA and tumor protein fragments.

The aim of dendritic cell therapy is to activate or strengthen the immune system. In immunotherapy, specific immune cells are used to target cancer cells. The therapy method uses so-called dendritic cells, which can recognize specific antigens on the surface of cancer cells. Thanks to improved tumor defense and a reduction in systemic side effects, the therapy is considered a promising treatment approach.